Company / Operating Income
Apellis Pharmaceuticals, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$55.4M
FY2025
5-year range
-$594.6M / $55.4M
FY2021-FY2025
Trend
+133.6%
vs FY2024
Sector context
#43 of 204
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s operating income of $55M is higher than 79% of companies in the Health Care sector (FY2025). Operating Income has increased for 3 consecutive years, from -$595M in FY2022 to $55M in FY2025.
Based on SEC 10-K filings.
$55M in FY2025. Top quartile in the Health Care sector.
Improved from -$517M to $55M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 204This company $55.4M Sector average $107.7M
▼
-48.5% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s operating income has grown for 3 consecutive years.
- In FY2025, operating income increased 133.6% year-over-year.
- Ranks #43 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $55.4M | +133.6% |
| FY2024 | -$165.0M | +68.1% |
| FY2023 | -$517.1M | +13.0% |
| FY2022 | -$594.6M | -10.9% |
| FY2021 | -$536.3M | -150.9% |
| FY2020 | -$213.7M | +25.8% |
| FY2019 | -$288.0M | -125.1% |
| FY2018 | -$127.9M | -152.0% |
| FY2017 | -$50.8M | -86.1% |
| FY2016 | -$27.3M | +41.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026